APOE and Alzheimer disease: Likewise, a cross-over study consisting of thirty days MCFA supplementation in AD patients, also resulted in an improvement in the ADAS-Cog-C score in ApoE4 negative patients and not in ApoE4 positive (only three individuals were ApoE4 positive) [92].